02.06.2013 Views

APPENDICES. A systematic review and economic model of the ...

APPENDICES. A systematic review and economic model of the ...

APPENDICES. A systematic review and economic model of the ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Study Intervention Participants Outcomes<br />

Core symptoms<br />

Not reported<br />

Reference<br />

Greenhill et al., 2002 59<br />

Co-existent problems<br />

Not reported<br />

Source<br />

Updated search<br />

Educational performance<br />

Not reported<br />

Arm 1<br />

MPH<br />

(Metadate CD): mean dose at week 3 was<br />

40.7 mg/day (1.28 mg/kg/day); once daily (a.m.)<br />

(range from 20 to 60 mg)<br />

(Administered by parent)<br />

Setting<br />

USA<br />

Psychological function<br />

Not reported<br />

Inclusion criteria<br />

1. 6–16 years <strong>of</strong> age<br />

2. No co-morbid psychiatric diagnosis; history <strong>of</strong><br />

seizure or tic disorder or a family history <strong>of</strong><br />

Tourette’s syndrome<br />

3. IQ > 80<br />

4. Children had to underst<strong>and</strong> study instruction<br />

5. No females who had undergone menarche<br />

6. No use <strong>of</strong> amphetamines, PEM or an<br />

investigational drug within 30 days <strong>of</strong> study entry;<br />

concomitant use <strong>of</strong> clonidine, anticonvulsant drugs<br />

or medications known to affect blood pressure,<br />

heart rate or CNS function<br />

7. No hyperthyroidism or glaucoma or any<br />

concurrent chronic or acute illness<br />

8. No prior non-reponse to a trial <strong>of</strong> stimulants for<br />

ADHD<br />

9. No previous requirement for a third daily dose in<br />

<strong>the</strong> afternoon or evening<br />

10. No documented allergy or intolerance to MPH<br />

11. Not currently living with anyone with a substance<br />

abuse disorder<br />

Arm 2<br />

Placebo<br />

(Administered by parent)<br />

Design<br />

Parallel trial<br />

Depression or anxiety<br />

Not reported<br />

Quality <strong>of</strong> life<br />

Conners’ Global Index: teacher; parent<br />

CGI-ratings<br />

Adverse events<br />

Teacher <strong>and</strong> Parent Side-Effect Questionnaires<br />

Additional outcomes<br />

Not reported<br />

Duration<br />

3 weeks<br />

Purpose<br />

To compare <strong>the</strong> efficacy,<br />

safety <strong>and</strong> tolerability <strong>of</strong><br />

once-daily<br />

administration <strong>of</strong><br />

modified-release MPH<br />

with placebo in children<br />

with ADHD<br />

© Queen’s Printer <strong>and</strong> Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />

Health Technology Assessment 2006; Vol. 10: No. 23<br />

Diagnostic criteria<br />

DSM-IV<br />

Number<br />

Total r<strong>and</strong>omised = 321 (male = 257?)<br />

Arm 1 = 158<br />

Arm 2 = 163<br />

Total withdrawals = 45<br />

Arm 1 = 17<br />

Arm 2 = 28<br />

314 children were included in <strong>the</strong> ITT efficacy<br />

population (MPH: n = 155, placebo; n = 159)<br />

Age<br />

9 years (mean); 5–15 years (range)<br />

IQ<br />

Not reported<br />

continued<br />

267

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!